Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

-IV Non-squamous non-small-cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of Apatinib in combination with

  • 12 views
  • 24 Feb, 2022
  • 1 location
Safety and Pharmacokinetics of REGN2810 (Cemiplimab) (Anti-PD-1) in Japanese Patients With Advanced Malignancies

treatment of Japanese patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) (Part 2, Cohort A) To evaluate tumor response ORR and DOR to cemiplimab plus chemotherapy as

ipilimumab
  • 15 views
  • 24 Mar, 2022
  • 20 locations
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy as a first-line treatment in patients with advanced non-squamous non-small cell lung

targeted therapy
cancer chemotherapy
carboplatin
EGFR
lung carcinoma
  • 0 views
  • 24 Mar, 2022
  • 1 location
Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

-type Genotype non-squamous Non-small Cell Lung Cancer.

cancer chemotherapy
non-squamous non-small cell lung cancer
carboplatin
EGFR
squamous non-small cell lung cancer
  • 0 views
  • 12 Mar, 2022
  • 1 location
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

non-small cell lung cancer with progression on or after platinum-based chemotherapy. Plinabulin inhibits tumor growth by targeting both new and existing blood vessels going to the tumor as well

nivolumab
cancer
platinum-based chemotherapy
measurable disease
systemic therapy
  • 0 views
  • 11 Mar, 2022
  • 1 location
Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. We hypothesized that Durvalumab in combination with standard chemotherapy is safe and effective

neutrophil count
cancer chemotherapy
platinum-based chemotherapy
platelet count
systemic therapy
  • 0 views
  • 03 Jul, 2022
  • 3 locations
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR a HER2 or a HER3 Mutation

the first stage and an additional 19 in the second stage (maximum total 87 patients) Indication : cancers harbouring an EGFR mutation(excluding non-squamous non- small cell lung cancer, a

  • 1 views
  • 22 Jan, 2021
  • 5 locations
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

recommended Phase 2 dose (RP2D) of GS-9716 in combination with either docetaxel or sacituzumab govitecan-hziy in adults with metastatic non-squamous non-small cell lung cancer (NSCLC) following treatment for

  • 0 views
  • 03 Jul, 2022
  • 5 locations
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors. The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab. Participants will be on this combination treatment for 21-day cycles. They will continue …

  • 8 views
  • 23 Mar, 2022
  • 3 locations
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated Chinese non-squamous NSCLC patients will be investigated in this clinical trial.

EGFR
pemetrexed
measurable disease
metastasis
vegf inhibitor
  • 3 views
  • 21 Mar, 2022
  • 1 location